Alphaeon Finds New Funding For Aesthetic Medicine Efforts

Irvine-based ALPHAEON Corporation, a developer of products aimed at the aesthetic medicine market, has raised a private funding, via a convertible note financing. Size of the funding was not announced. the company said the funding was led by Dental Innovations BVBA, plus Sailing Capital, Longitude Capital Management Co., LLC and other current investors. Alpheon's lead candidate is DWP-450 (Botulinum toxin Type A), a product candidate for the treatment of adult patients with glabellar lines (the frown lines between the eyebrows). The company's CEO is Murthy Simhambhatla. More information »